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• 710,000 people living with dementia 
• Less than half have a diagnosis 
• Impact on quality of life 
• Costs society £23 billion a year 
• Costs fall primarily to people with dementia, their 
families & social care 
• PM Challenge - target of two-thirds ‘to be 
identified and given appropriate support’ by 2015 
Dementia (England and Wales) 
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What did we look at? 
• One-off cognitive test for people age 75 
• Possibly as part of another appointment such 
as a health check 
• ‘Timely’ diagnosis (MMSE <24) 
• 391,400 people age 75 
• 16,800 (4.3%) with dementia 
• 9400 do not have a diagnosis 
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Cognitive testing 
• Primary care setting 
• MMSE standard 15 minute appointment (or as part of 
other appointment) 
• Clinical nurses and GPs 
• 19% refuse a cognitive test (Holsinger et al., 2011) 
• 89% sensitivity (11% with dementia not identified)  
• 95.5% specificity (4.5% without dementia identified) 
• 311,000 receive a cognitive test 
• Cost - £10 million 
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Further diagnostic tests 
• 2 specialist visits 
• MRI or CT for 75% of people 
• Average £540 per person 
• 48% might refuse further diagnostic tests 
(Boustani et al., 2005) 
• 10,600 go for further diagnostic testing 
• Cost - £6 million 
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Interventions (person with dementia) 
• Medications  
– 12 month treatment, £815 
– delay to residential care of 47 days (marginal cost 
of care £46 per day) 
• CST  
– 8 week treatment, £300  
– cognition (0.48 SMD), communication (0.44 SMD) 
and quality of life (0.38 SMD).  
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Interventions (caregiver) 
• Multi-component support  
– 0.39 resident caregivers, 0.32 non-resident adult 
children, 0.15 no caregiver, 14% other 
– 75% take up, 18% drop-out (52% of people 
diagnosed) 
– 10 hours counselling/ support, £475 
– median delay to residential care, 557 days (20% 
benefits for non-resident), £46 marginal cost of 
care per day  
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Interventions (caregiver) 
• Psychological therapy 
– 33% in distress, £412 
– Reductions in depression (0.66 SMD), anxiety 
(0.21 SMD) 
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Results 
As a result … 
• 3,500 people would receive diagnosis (3395 to 
7592)  
• 2150 otherwise would never be diagnosed 
• Remaining 1350 diagnosed earlier 
• 13,650 ‘false positives’ (3,035 to 24,282).  
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Costs and savings 
• Potential societal net costs associated with the 
screening programme of £236,012 were 
identified (almost cost-neutral)  
• In sensitivity analyses, ranged from net costs 
of £3,649,794 to net savings of £4,685,768. 
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Conclusion 
• Limited amount of robust evidence 
• Limitations of model (e.g. no dynamic factors) 
• Importance of caregiver support 
• Highly conservative assumptions 
• Excludes many potential harms and benefits 
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This presentation describes independent research funded by Bupa.  
The views expressed here are those of the presenters/authors and 
not necessarily those of Bupa. 
 
• Josie Dixon, Research Fellow, Personal Social 
Services Research Unit, LSE (j.e.dixon@lse.ac.uk) 
 
• Martin Knapp, Professor of Social Policy, LSE; 
Director of Personal Social Services Research Unit, 
LSE; Director of NIHR School for Social Care 
Research (m.knapp@lse.ac.uk) 
